Global Restriction Endonucleases Products (REP) Market: Thrust on Research and Development makes Europe and North America Leaders

Restriction endonucleases (RE), also known as restriction enzymes, are extracted from bacteria and find application in research in molecular biology. They are used, for example, as primary reagents in procedures such as genomic mapping, restriction fragment length polymorphism (RFLP), recombinant processes, and DNA sequencing. They are also used for commercial purposes.

Obtain the Futuristic Market Growth Prospects of Restriction Endonucleases Products at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4175

Restriction endonucleases are classified into types I, II, III and IV. Among them, enzymes categorized under class II enjoy maximum popularity on account of their usefulness in specific determination of the DNA sequences and for generating termini with 5’ phosphate and 3’ hydroxyl groups, and their capability to recognize non-palindromic sequences. So far, over 10,000 bacteria have been screened for restriction enzymes and more than 2,500 restriction enzymes having over 250 distinct specificities in sequences have been unearthed. The microorganisms that create RE also manufacture DNA methyltransferases – a feature that prevents their own DNA from cleavage.

REs are used in conventional cloning, deciphering epigenetic modifications, building of DNA libraries, and in vivo gene editing. The restriction endonucleases market has been divided according to both type and application by the TMR report. The market for restriction endonucleases products is predicted to grow due to the rising use of the enzymes in molecular biology techniques and processes followed by various research and development activities making use of these enzymes. Factors that have the potential to restrict market growth are expensive downstream activities and unreliability of the enzymes in providing accurate results.

Geography-wise, the TMR report segments the global REP market into Europe, North America, Asia Pacific, and the Rest of the World. So far, Europe and North America have dominated on the revenue front due to the increasing thrust on research and development resulting from the presence of a large number of manufacturers in these regions. Asia Pacific and the Rest of the World (RoW) are the most promising markets due to governments in various countries in the region pumping more money into research and development, which has resulted in the commercial production of these enzymes.

Read the Present Market Structure of Restriction Endonucleases Products at: http://www.transparencymarketresearch.com/restriction-endonucleases-products-market.html

The report by TMR leverages various analytical tools such as Porter’s Five Forces analysis and SWOT analysis to gauge the current competitive landscape in the global market for REP. Some of the important companies listed in report are Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Genetix Biotech Asia Pvt. Ltd., Inc., and ThermoFisher Scientific, Inc.

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.